前列腺癌中雄激素受体的新进展：第 1 届国际雄激素受体研讨会报告。
New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium.
机构信息
Department of Urology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
出版信息
J Transl Med. 2024 Jan 18;22(1):71. doi: 10.1186/s12967-024-04878-5.
The androgen receptor (AR) is a crucial player in various aspects of male reproduction and has been associated with the development and progression of prostate cancer (PCa). Therefore, the protein is the linchpin of current PCa therapies. Despite great research efforts, the AR signaling pathway has still not been deciphered, and the emergence of resistance is still the biggest problem in PCa treatment. To discuss the latest developments in AR research, the "1st International Androgen Receptor Symposium" offered a forum for the exchange of clinical and scientific innovations around the role of the AR in prostate cancer (PCa) and to stimulate new collaborative interactions among leading scientists from basic, translational, and clinical research. The symposium included three sessions covering preclinical studies, prognostic and diagnostic biomarkers, and ongoing prostate cancer clinical trials. In addition, a panel discussion about the future direction of androgen deprivation therapy and anti-AR therapy in PCa was conducted. Therefore, the newest insights and developments in therapeutic strategies and biomarkers are discussed in this report.
雄激素受体 (AR) 在男性生殖的各个方面都起着至关重要的作用，并且与前列腺癌 (PCa) 的发展和进展有关。因此，该蛋白是目前前列腺癌治疗的关键。尽管进行了大量的研究工作，但 AR 信号通路仍未被破译，耐药性的出现仍然是前列腺癌治疗的最大问题。为了讨论 AR 研究的最新进展，“第 1 届国际雄激素受体研讨会”提供了一个交流平台，讨论了 AR 在前列腺癌 (PCa) 中的作用的临床和科学创新，并激发了来自基础、转化和临床研究的领先科学家之间的新的合作互动。该研讨会包括三个部分，涵盖了临床前研究、预后和诊断生物标志物以及正在进行的前列腺癌临床试验。此外，还就雄激素剥夺治疗和抗 AR 治疗在前列腺癌中的未来方向进行了小组讨论。因此，本报告讨论了治疗策略和生物标志物方面的最新见解和进展。
Zotero 插件